Logo

American Heart Association

  24
  0


Final ID: Mo1042

Targeting Asprosin For Treatment of Hypertension

Abstract Body (Do not enter title and authors here): Background: Hypertension is a leading risk factor for cardiovascular disease and is strongly associated with metabolic syndrome (MS), particularly obesity, through complex and multifactorial mechanisms. Asprosin, a recently discovered adipokine, has been positively correlated with several metabolic conditions, including obesity, type 2 diabetes, polycystic ovary syndrome (PCOS), fatty liver disease, and cardiovascular diseases such as coronary artery disease and hypertension. Asprosin’s two well-characterized metabolic roles include promoting hepatic gluconeogenesis and stimulating appetite by activating AgRP+ neurons in the hypothalamus. Furthermore, new findings suggest that asprosin signaling in the paraventricular nucleus causes a significant increase in blood pressure. In previous experiments, we demonstrated that neutralizing asprosin with anti-asprosin monoclonal antibodies significantly reduced appetite and corrected hyperglycemia in obese and diabetic mice. However, it remains unknown whether neutralizing asprosin also confers protection against hypertension.
Hypothesis: We hypothesized that neutralization of asprosin signaling could serve as a viable therapeutic strategy for treating hypertension.
Methods: We treated LepRdb/db mice (a model of hypertension, type 2 diabetes, and obesity) and littermate controls (LepRdb/+) with anti-asprosin monoclonal antibodies and measured blood pressure using the tail-cuff method.
Results and Conclusion: Neutralizing asprosin significantly reduced the blood pressure of hypertensive LepRdb/db mice. These findings suggest that targeting asprosin therapeutically may offer a promising "one remedy for three maladies" approach to simultaneously treat obesity, type 2 diabetes, and hypertension.
  • Voisard, Layne  ( University of Kentucky , Lexington , Kentucky , United States )
  • Anderson, Emma  ( University of Kentucky , Lexington , Kentucky , United States )
  • Akbar, Rubab  ( University of Kentucky , Lexington , Kentucky , United States )
  • Mishra, Ila  ( University of Kentucky , Lexington , Kentucky , United States )
  • Author Disclosures:
    Layne Voisard: DO NOT have relevant financial relationships | Emma Anderson: No Answer | Rubab Akbar: No Answer | Ila Mishra: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Hypertension: Spanning the Gamut

Monday, 11/10/2025 , 10:30AM - 11:30AM

Abstract Poster Board Session

More abstracts on this topic:
Personal Care Product Usage Patterns And Hypertension In U.S. Women From The Sister Study

Lim Jungeun, Chang Che-jung, White Alexandra, Lo Shelton, Wang Hantao, Goodney Gabriel, Roger Veronique, Sandler Dale, Wong Jason

Microplastic exposure elicits sex-specific atherosclerosis development in low-density lipoprotein receptor-deficient mice.

Lin Ting-an, Nguyen Mya, Pan Jianfei, Ma Qianyi, Sun Liang, Chen Hong, Zhou Changcheng

You have to be authorized to contact abstract author. Please, Login
Not Available